Actinomycetes are known for their large genetic potential to produce several distinct classes of secondary metabolites. 1 While cultivating Actinomadura sp. DSMZ 13491, the producer of the cyclic heptapeptide GE23077, 2 we observed it produced an antibacterial activity. Despite being a potent and selective inhibitor of bacterial RNA polymerase, GE23077 is devoid of activity against bacterial cells, except for marginal activity against some Moraxella spp. 2 Here we report on the isolation, structure elucidation and properties of madurastatin C1 (1), the antimicrobial compound produced by this actinomycete.
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A 10-ml seed culture of Actinomadura sp. DSMZ 13491, prepared by inoculating a frozen cell stock into 30 ml of AFT medium (2% glucose, 0.2% yeast extract, 0.8% soybean meal, 0.5% tryptone, 0.1% NaCl, 0.4% CaCO 3 , adjusted to pH 7.2 with 0.1 N NaOH before sterilization) and incubating for 72-96 h, was transferred into 200 ml of fresh AFT medium. The production of antibacterial activity was monitored over time by depositing 10 ml of a microbial extract, prepared as described by Pozzi et al., 3 onto Muller Hinton Agar (Difco Laboratories, Detroit, MI, USA) plates, previously inoculated with 10 5 cfu ml À1 Staphylococcus aureus ATCC 6538P or Micrococcus luteus ATCC 10240. An inhibition halo was clearly observed on M. luteus plates after 24 h of cultivation, whereas only a weak activity was visible on the S. aureus plates. An HPLC analysis of the culture extract is shown in Figure 1a . A major peak was observed at 2.6 min with a m/z of 592 [M+H] + , whereas the two major congeners of GE23077, with m/z of 804 and 806, were observed at 1.8 min, as expected. 2 Minor peaks were also observed at 2.1 min, with m/z of 610 and 645. The 2.6-min metabolite was purified by medium pressure chromatography on a reverse-phase C18 RediSep RF column, using a CombiFlash RF Teledyne Isco Medium Pressure Chromatography System (Teledyne ISCO, Lincoln, NE, USA). The column was previously conditioned with a mixture of phase A (50 mM HCOONH 4 ), phase B (CH 3 CN) 95:5 (v/v), and eluted with a 15-min linear gradient from 5 to 95% phase B. The active fractions were collected, concentrated under vacuum and lyophilized, yielding 13 mg of purified 1 (estimated at least 95% pure by NMR).
NMR and MS analyses of 1 indicated high similarity with the siderophores named madurastatins. 4 1 H-and 13 C-NMR data (Table 1) indicated the presence of an ortho disubstituted benzene, as confirmed by bidimensional experiments showing four aromatic protons with a TOCSY correlation. In particular, a doublet at 7.61 p.p.m. had a COSY correlation with a pseudo-triplet at 6.82 p.p.m., and a doublet at 6.89 p.p.m. correlated with a pseudotriplet at 7.34 p.p.m., whereas the pseudo-triplet signals intercorrelated. HMBC experiments demonstrated the disubstituted benzene to be a salicylic acid residue. Five aliphatic spin systems were also observed by using homo-and hetero-nuclear 2D-NMR experiments. COSY and TOCSY correlations evidenced the presence of an aziridine group and of a six-membered lactam at the C-terminus. A strong HMBC correlation between the methyl group at 2.54 p.p.m. and the a-carbon at 61.3 p.p.m. confirmed the presence of an N-methyl group. NMR data demonstrated that 1 is a pentapeptide carrying a salicylate at the N-terminus. Thus, 1 is highly related to madurastatin A1, except for the lack of the C-16 methyl, which probably originates from incorporation of glycine instead of alanine. This is confirmed by the occurrence of a signal at 3.82 p.p.m., integrating two protons, corresponding to the CH 2 at position 16. The structure of 1 as established by NMR is also supported by MS n analysis. Its fragmentation pathway, as described in Figure 1b , showed a typical peptide fragmentation, identical to that reported for madurastatin A1, 4 except for the difference at C-16, whereas 1 produced fragments of m/z 219 and 403, ions of m/z 233 and 417 were reported for madurastatin A1. 4 As described for madurastatin A1, 4 a characteristic bathochromic shift (from 254 and 310 nm to 280 and 445 nm) was observed when 1 mg was added to 1 ml 0.6 M FeCl 3 (data not shown), confirming the high chelating affinity for ferric ions.
By analogy with madurastatin A1, 4 we can infer that m/z 610 and 645 present in the 2.1-min peak (Figure 1a ) correspond to 1 hydrolyzed at the aziridine ring (position C-19) and to the 1-Fe +3 complex, respectively. Consistently, the compound at m/z 610 yields an MS fragment at 480 amu, instead of 462 amu as seen with 1 (data not shown). Moreover, the conversion of the m/z 592 to 645 was observed upon addition of 1 to the FeCl 3 aqueous solution. Although inhibition halos of 25 and 5 mm were observed with M. luteus and S. aureus, respectively, when spotting 50 mg of 1 onto Muller Hinton Agar plates, neither 1-hydrolyzed nor 1-Fe 3+ complex showed antimicrobial activity when tested with M. luteus, confirming the important role of the aziridine ring for the biological activity.
In conclusion, Actinomadura sp. DSMZ 13491 can produce a second bioactive metabolite in addition to GE23077. Earlier experiments had indeed shown that the genome of this strain encodes at least 12 nonribosomal peptide modules. 5 Although we do not know the relatedness between the Actinomadura strain described by Harada et al. 4 and ours, it is remarkable that a sputum-and a soil-derived strain produce very similar compounds without the need for iron limited media, as seen instead with other actinomycetes. 6-9 
